Ziprasidone: a new atypical antipsychotic.
This paper reviews the clinical pharmacology, efficacy and safety of the new atypical antipsychotic, ziprasidone. All published citations regarding ziprasidone were retrieved and reviewed using a MEDLINE search (completed for citations to early 2001). In addition, abstracts from recent scientific meetings presenting data not yet published were reviewed. Like other new antipsychotic medications, ziprasidone fits the profile of an atypical agent, exerting efficacy in positive and negative symptoms of psychosis, as well as affective symptoms, with a low risk of neurological and neuroendocrinological side effects. Unlike newer agents, it does not appear to be associated with weight gain in most patients.
Keck
P E
PE
Department of Psychiatry, University of Cincinnati College of Medicine, Ohio, USA.
McElroy
S L
SL
Arnold
L M
LM
D014150:Antipsychotic Agents / Q000627:therapeutic use*; D001569:Benzodiazepines; D002986:Clinical Trials as Topic; D003987:Dibenzothiazepines / Q000627:therapeutic use; D018492:Dopamine Antagonists / Q000627:therapeutic use; D004347:Drug Interactions; D017408:Guidelines as Topic; D006801:Humans; D000077152:Olanzapine; D010879:Piperazines / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D010890:Pirenzepine / Q000031:analogs & derivatives / Q000627:therapeutic use; D000069348:Quetiapine Fumarate; D018967:Risperidone / Q000627:therapeutic use; D012559:Schizophrenia / Q000188:drug therapy*; D012702:Serotonin Antagonists / Q000627:therapeutic use; D013844:Thiazoles / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D013997:Time Factors; D005879:Tourette Syndrome / Q000188:drug therapy
D014150:Antipsychotic Agents; D003987:Dibenzothiazepines; D018492:Dopamine Antagonists; D010879:Piperazines; D012702:Serotonin Antagonists; D013844:Thiazoles; D001569:Benzodiazepines; D000069348:Quetiapine Fumarate; D010890:Pirenzepine; C092292:ziprasidone; D018967:Risperidone; D000077152:Olanzapine